{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:42:36Z","timestamp":1760143356737,"version":"build-2065373602"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Prior speculation suggests that selective 5-hydroxytryptamine-3 receptors and neurokinin-1 receptor antagonists may increase arrhythmia risk and induce electrocardiographic changes. This study examined the effect of anti-emetic medications on arrhythmogenic potential and hemodynamic alterations. Methods: We considered patients aged 18 or above receiving chemotherapy between June 2013 and December 2013. Patients were grouped by anti-emetic medication: intravenous granisetron (Group G), oral aprepitant plus IV granisetron (Group AG), IV palonosetron (Group P), and oral aprepitant plus IV palonosetron (Group AP). We recorded blood pressure and electrocardiography initially and at the thirtieth minute post-medication, focusing on P dispersion, QTc dispersion, and systolic\/diastolic blood pressure alterations. Results: The study included 80 patients (20 per group). Baseline systolic\/diastolic blood pressure and P dispersion showed no significant variance. However, the baseline QTc dispersion was significantly lower in Groups P and AP than G and AG. The thirtieth-minute systolic\/diastolic blood pressures were significantly lower than the baseline for Groups AG and AP, and the heart rates decreased in all groups. Group P showed significantly fewer blood pressure changes. Conclusions: We found no arrhythmogenic potential linked to granisetron, palonosetron, and aprepitant. Hypotension was more frequent at 30 min post-medication in granisetron or aprepitant recipients. Considering no hypotension occurred when using palonosetron alone, this treatment was deemed safer.<\/jats:p>","DOI":"10.3390\/jcm13030843","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T09:43:22Z","timestamp":1706780602000},"page":"843","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Selective 5-Hydroxytryptamine-3 Receptor and Neurokinin-1 Receptor Antagonists on Hemodynamic Changes and Arrhythmogenic Potential in Patients Receiving Chemotherapy: A Retrospective, Observational Study"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5483-9758","authenticated-orcid":false,"given":"Utku Burak","family":"Bozbulut","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, VM Medical Mersin Hospital, Mersin 33200, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6222-2878","authenticated-orcid":false,"given":"Tu\u011fba","family":"Cengiz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Ankara Bilkent City Hospital, Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara Gazi University, Ankara 06500, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"ref_1","first-page":"157","article-title":"Comparison of the Anti-emetic Effect of Aprepitant\/granisetron and Palonosetron Combined with Dexamethasone in Gynecological Cancer Patients Treated with Paclitaxel and Carboplatin Combination Regimen","volume":"77","author":"Obayashi","year":"2022","journal-title":"Die Pharm.-Int. J. Pharm. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b21-00198","article-title":"Palonosetron versus Granisetron in Combination with Aprepitant and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting after Moderately Emetogenic Chemotherapy: A Single-Institutional Retrospective Cohort Study","volume":"44","author":"Miyoshi","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00280-019-03831-4","article-title":"Comparison of palonosetron and granisetron in triplet anti-emetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: A multicenter, prospective, and observational study","volume":"83","author":"Araz","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1248\/bpb.b20-00609","article-title":"Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study","volume":"44","author":"Hamano","year":"2021","journal-title":"Biol. Pharm. Bull."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1002\/cam4.3123","article-title":"Efficacy of NEPA, a fixed anti-emetic combination of netupitant and palonosetron, vs. a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study","volume":"9","author":"Chang","year":"2020","journal-title":"Cancer Med."},{"key":"ref_6","first-page":"CD012775","article-title":"Anti-emetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: A network meta-analysis","volume":"11","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00280-021-04257-7","article-title":"Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy","volume":"88","author":"Mahrous","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s00520-018-4403-y","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet anti-emetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: Analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support. Care Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tricco, A.C., Blondal, E., Veroniki, A.A., Soobiah, C., Vafaei, A., Ivory, J., Strifler, L., Cardoso, R., Reynen, E., and Nincic, V. (2016). Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: A systematic review and network meta-analysis. BMC Med., 14.","DOI":"10.1186\/s12916-016-0761-9"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1517\/14740338.2014.954546","article-title":"5-Hydroxytryptamine3 receptor antagonists and cardiac side effects","volume":"13","author":"Brygger","year":"2014","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1345\/aph.1C510","article-title":"Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists","volume":"37","author":"Navari","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.coc.0000144849.41300.0a","article-title":"The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia","volume":"28","author":"Buyukavci","year":"2005","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/pbc.20639","article-title":"Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer","volume":"47","author":"Pinarli","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1213\/ane.0b013e3181ac1066","article-title":"Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects","volume":"109","author":"Marbury","year":"2009","journal-title":"Anesth. Analg."},{"key":"ref_15","first-page":"CD012859","article-title":"Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: A network meta-analysis","volume":"10","author":"Weibel","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0959-8049(03)00120-5","article-title":"Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: Results of a pilot study","volume":"39","author":"Aapro","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF00685640","article-title":"An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease","volume":"37","author":"Carmichael","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40780-017-0097-4","article-title":"Anti-emetic efficacy and safety of granisetron or palonosetron alone and in combination with a corticosteroid for ABVD therapy-induced nausea and vomiting","volume":"4","author":"Uchida","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/annonc\/mdx698","article-title":"A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed anti-emetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)","volume":"29","author":"Zhang","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_20","first-page":"304","article-title":"Comparison of anti-emetic effects of granisetron and palonosetron in patients receiving bendamustine-based chemotherapy","volume":"73","author":"Uchida","year":"2018","journal-title":"Die Pharm.-Int. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/BF00689445","article-title":"Possible cardiac side effects of granisetron, an anti-emetic agent, in patients with bone and soft-tissue sarcomas receiving cytotoxic chemotherapy","volume":"35","author":"Watanabe","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18773\/austprescr.2020.011","article-title":"Anti-emetic drugs: What to prescribe and when","volume":"43","author":"Athavale","year":"2020","journal-title":"Aust. Prescr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10903127.2010.519822","article-title":"Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics","volume":"15","author":"Salvucci","year":"2011","journal-title":"Prehosp Emerg. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00520-011-1239-0","article-title":"A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy","volume":"20","author":"Aogi","year":"2012","journal-title":"Support. Care Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1248\/bpb.b17-00318","article-title":"Comparison between Anti-emetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP","volume":"40","author":"Uchida","year":"2017","journal-title":"Biol. Pharm. Bull."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/843\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:52:58Z","timestamp":1760104378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13030843"],"URL":"https:\/\/doi.org\/10.3390\/jcm13030843","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}